Nuclear transport modulators and uses thereof
View Patent ↗The invention generally relates to the field of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to new substituted-heterocyclic azole compounds, the synthesis and use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity such as in treating cancer and other neoplastic disorders, inflammatory diseases, disorders of abnormal tissue growth and fibrosis including cardiomyopathy, pulmonary fibrosis, hepatic fibrosis, glomerulonephritis, and other renal disorders, and for the treatment of viral infections (both acute and chronic).
1. A compound of formula III′:
or a pharmaceutically acceptable salt thereof, wherein:
A′ is phenyl substituted with one or more R 1″ ;
each R 1′ is independently selected from the group consisting of halogen, —NO 2 , —CN, —OR a , —SR a , —N(R a ) 2 , —N 3 , or -L 1 -R;
each R a is independently —H, —R or —C(O)R;
L 1 is a covalent bond or an optionally substituted bivalent C 1-6 hydrocarbon chain, wherein one or more methylene units of L 1 is optionally and independently replaced by —Cy—, —O—, —S—, —N(R a )—, —C(O)—, —C(S)—, —C(O)N(R a )—, —N(R a )C(O)N(R a )—, —N(R a )C(O)—, —N(R a )C(O)O—, —OC(O)N(R a )—, —S(O)—, —S(O) 2 —, —S(O) 2 N(R a )—, —N(R a )S(O) 2 —, —OC(O)—, or —C(O)O—;
—Cy— is an optionally substituted bivalent ring selected from a 3-7 membered saturated or partially unsaturated cycloalkylene ring, a 4-7 membered saturated or partially unsaturated heterocycloalkylene ring having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur, phenylene, a 5-6 membered monocyclic heteroarylene having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, an 8-10 membered bicyclic arylene, or an 8-10 membered bicyclic heteroarylene having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur;
each R is independently optionally substituted C 1-8 alkyl; C 2-8 alkenyl; C 2-8 alkynyl; haloalkyl; phenyl; a 3-7 membered saturated or partially unsaturated cycloalkyl ring; an 8-10 membered bicyclic saturated, partially unsaturated or aryl carbocyclic ring; a 4-7 membered saturated or partially unsaturated heterocycloalkyl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or:
two R on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur; and
R 3′ is -L 1 -R, wherein L 1 is —CH 2 — and R is a 5-6 membered monocyclic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur.
2. The compound according to claim 1 , wherein R 3′ is wherein L 1 is —CH 2 — and R is a 6-membered monocyclic heterocyclic ring having 1-3 nitrogens.
3. The compound according to claim 1 , selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
4. A compound of formula III′:
or a pharmaceutically acceptable salt thereof, wherein:
A′ is phenyl substituted with one or more R 1′ ;
each R 1′ is independently selected from the group consisting of halogen, —NO 2 , —CN, —OR a , —SR a , —N(R a ) 2 , —N 3 , or -L 1 -R;
each R a is independently —H, —R or —C(O)R;
L 1 is a covalent bond or an optionally substituted bivalent C 1-6 hydrocarbon chain, wherein one or more methylene units of L 1 is optionally and independently replaced by —Cy—, —O—, —S—, —N(R a )—, —C(O)—, —C(S)—, —C(O)N(R a )—, —N(R a )C(O)N(R a )—, —N(R a )C(O)—, —N(R a )C(O)O—, —OC(O)N(R a )—, —S(O)—, —S(O) 2 —, —S(O) 2 N(R a )—, —N(R a )S(O) 2 —, —OC(O)—, or —C(O)O—;
—Cy— is an optionally substituted bivalent ring selected from a 3-7 membered saturated or partially unsaturated cycloalkylene ring, a 4-7 membered saturated or partially unsaturated heterocycloalkylene ring having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur, phenylene, a 5-6 membered monocyclic heteroarylene having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, an 8-10 membered bicyclic arylene, or an 8-10 membered bicyclic heteroarylene having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur;
each R is independently optionally substituted C 1-8 alkyl; C 2-8 alkenyl; C 2-8 alkynyl; haloalkyl; phenyl; 3-7 membered saturated or partially unsaturated cycloalkyl ring; 8-10 membered bicyclic saturated, partially unsaturated or aryl carbocyclic ring; 4-7 membered saturated or partially unsaturated heterocycloalkyl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 5-6 membered monocyclic heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or:
two R on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur; and
R 3′ is —CH(CH 3 ) 2 .
5. The compound according to claim 4 , selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
6. The compound according to claim 5 , selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
7. A compound selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.